{'fraction_non_alphanumeric': 0.018885741265344664, 'fraction_numerical': 0.0, 'mean_word_length': 5.708860759493671, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Old and new dopamine agonists in Parkinson's disease

This work gives a comprehensive overview of the basis and clinical neuropharmacology of dopamine agonists and the rationale for their employment in Parkinson's disease. This up-to-date guide covers such topics as the pathophysiology of dopaminergic systems and the neuro-biochemistry agonists, both in the first-time treatment of PD patients and for reducing motor fluctuations in levodopa-treated ones, and the possible role of dopamine agonists as neuroprotective agents. Particular emphasis has been placed on apomorphine, an old dopamine agonist that has recently recaptured neurologists' interest for its use in both diagnostic use and therapeutic management of advanced Parkinsonian patients. The book is a compendium that assembles the entire spectrum of current basic and clinical research on dopaminergic systems and dopamine agonists in Parkinson's disease into a single reference source. It should be of interest to neurophysiologists, psychiatrists, pharmacologists, researchers and residents.